Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Building research capacity through "Planning for Success".

Gómez L, Jaramillo A, Halpaap B, Launois P, Cuervo LG, Saravia NG.

PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007426. doi: 10.1371/journal.pntd.0007426. eCollection 2019 Aug. No abstract available.

2.

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions.

Regli IB, Fernández OL, Martínez-Salazar B, Gómez MA, Saravia NG, Tacchini-Cottier F.

Front Immunol. 2018 Dec 21;9:3040. doi: 10.3389/fimmu.2018.03040. eCollection 2018.

3.

Developing mobile health applications for neglected tropical disease research.

Navarro A, Rubiano L, Arango JD, Rojas CA, Alexander N, Saravia NG, Aronoff-Spencer E.

PLoS Negl Trop Dis. 2018 Nov 1;12(11):e0006791. doi: 10.1371/journal.pntd.0006791. eCollection 2018 Nov. Review.

4.

Strengthening institutional capacity for equitable health research: lessons from Latin America and the Caribbean.

Tulloch-Reid MK, Saravia NG, Dennis RJ, Jaramillo A, Cuervo LG, Walker SP, Salicrup LA.

BMJ. 2018 Jul 16;362:k2456. doi: 10.1136/bmj.k2456. No abstract available.

5.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.

6.

Pathophysiology of Leishmania Infection during Pregnancy.

Berger BA, Bartlett AH, Saravia NG, Galindo Sevilla N.

Trends Parasitol. 2017 Dec;33(12):935-946. doi: 10.1016/j.pt.2017.08.012. Epub 2017 Oct 4. Review.

PMID:
28988681
7.

Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Barrera MC, Rojas LJ, Weiss A, Fernandez O, McMahon-Pratt D, Saravia NG, Gomez MA.

Acta Trop. 2017 Dec;176:355-363. doi: 10.1016/j.actatropica.2017.08.017. Epub 2017 Aug 24.

8.

Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis.

Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, Cossio A, Casadiego Rincón EJ, Desai MM, Saravia NG, Gómez MA.

PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713. doi: 10.1371/journal.pntd.0005713. eCollection 2017 Jul.

9.

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.

Berger BA, Cossio A, Saravia NG, Castro MDM, Prada S, Bartlett AH, Pho MT.

PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005459. doi: 10.1371/journal.pntd.0005459. eCollection 2017 Apr.

10.

Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.

Ehrlich AK, Fernández OL, Rodriguez-Pinto D, Castilho TM, Corral Caridad MJ, Goldsmith-Pestana K, Saravia NG, McMahon-Pratt D.

Infect Immun. 2017 Feb 23;85(3). pii: e00981-16. doi: 10.1128/IAI.00981-16. Print 2017 Mar.

11.

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Castro MD, Gomez MA, Kip AE, Cossio A, Ortiz E, Navas A, Dorlo TP, Saravia NG.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02198-16. doi: 10.1128/AAC.02198-16. Print 2017 Mar.

12.

An Innovative Field-Applicable Molecular Test to Diagnose Cutaneous Leishmania Viannia spp. Infections.

Saldarriaga OA, Castellanos-Gonzalez A, Porrozzi R, Baldeviano GC, Lescano AG, de Los Santos MB, Fernandez OL, Saravia NG, Costa E, Melby PC, Travi BL.

PLoS Negl Trop Dis. 2016 Apr 26;10(4):e0004638. doi: 10.1371/journal.pntd.0004638. eCollection 2016 Apr.

13.

Parasitological Confirmation and Analysis of Leishmania Diversity in Asymptomatic and Subclinical Infection following Resolution of Cutaneous Leishmaniasis.

Rosales-Chilama M, Gongora RE, Valderrama L, Jojoa J, Alexander N, Rubiano LC, Cossio A, Adams ER, Saravia NG, Gomez MA.

PLoS Negl Trop Dis. 2015 Dec 11;9(12):e0004273. doi: 10.1371/journal.pntd.0004273. eCollection 2015 Dec.

14.

Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.

Gonzalez-Fajardo L, Fernández OL, McMahon-Pratt D, Saravia NG.

PLoS Negl Trop Dis. 2015 May 29;9(5):e0003820. doi: 10.1371/journal.pntd.0003820. eCollection 2015 May.

15.

First report of Warileya rotundipennis (Psychodidae: Phlebotominae) naturally infected with Leishmania (Viannia) in a focus of cutaneous leishmaniasis in Colombia.

Moreno M, Ferro C, Rosales-Chilama M, Rubiano L, Delgado M, Cossio A, Gómez MA, Ocampo C, Saravia NG.

Acta Trop. 2015 Aug;148:191-6. doi: 10.1016/j.actatropica.2015.04.017. Epub 2015 Apr 25.

16.

Sensitive diagnosis of cutaneous leishmaniasis by lesion swab sampling coupled to qPCR.

Adams ER, Gomez MA, Scheske L, Rios R, Marquez R, Cossio A, Albertini A, Schallig H, Saravia NG.

Parasitology. 2014 Dec;141(14):1891-7. doi: 10.1017/S0031182014001280. Epub 2014 Aug 11.

17.

Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.

Fernández OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S, Rodríguez I, Gomez MA, Saravia NG.

PLoS Negl Trop Dis. 2014 May 22;8(5):e2871. doi: 10.1371/journal.pntd.0002871. eCollection 2014 May.

18.

Chronicity of dermal leishmaniasis caused by Leishmania panamensis is associated with parasite-mediated induction of chemokine gene expression.

Navas A, Vargas DA, Freudzon M, McMahon-Pratt D, Saravia NG, Gómez MA.

Infect Immun. 2014 Jul;82(7):2872-80. doi: 10.1128/IAI.01133-13. Epub 2014 Apr 21.

19.

CD4 T cell activation by B cells in human Leishmania (Viannia) infection.

Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D.

BMC Infect Dis. 2014 Feb 25;14:108. doi: 10.1186/1471-2334-14-108.

20.

Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.

Gómez MA, Navas A, Márquez R, Rojas LJ, Vargas DA, Blanco VM, Koren R, Zilberstein D, Saravia NG.

J Antimicrob Chemother. 2014 Jan;69(1):139-49. doi: 10.1093/jac/dkt334. Epub 2013 Aug 24.

21.

Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment.

Blanco VM, Cossio A, Martinez JD, Saravia NG.

Am J Trop Med Hyg. 2013 Aug;89(2):359-64. doi: 10.4269/ajtmh.12-0784. Epub 2013 Jun 24.

22.

Detection of Leishmania RNA virus in Leishmania parasites.

Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J, Hartley MA, Prevel F, Castiglioni P, Pratlong F, Bastien P, Müller N, Parmentier L, Saravia NG, Beverley SM, Fasel N.

PLoS Negl Trop Dis. 2013;7(1):e2006. doi: 10.1371/journal.pntd.0002006. Epub 2013 Jan 10.

23.

Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response.

Ramírez C, Díaz-Toro Y, Tellez J, Castilho TM, Rojas R, Ettinger NA, Tikhonova I, Alexander ND, Valderrama L, Hager J, Wilson ME, Lin A, Zhao H, Saravia NG, McMahon-Pratt D.

PLoS Negl Trop Dis. 2012;6(10):e1866. doi: 10.1371/journal.pntd.0001866. Epub 2012 Oct 25.

24.

Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species.

Rodriguez-Pinto D, Navas A, Blanco VM, Ramírez L, Garcerant D, Cruz A, Craft N, Saravia NG.

PLoS Negl Trop Dis. 2012;6(4):e1627. doi: 10.1371/journal.pntd.0001627. Epub 2012 Apr 24.

25.

Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.

Fernández O, Diaz-Toro Y, Valderrama L, Ovalle C, Valderrama M, Castillo H, Perez M, Saravia NG.

J Clin Microbiol. 2012 Jul;50(7):2207-11. doi: 10.1128/JCM.00216-12. Epub 2012 Apr 18.

26.

Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis.

Walker J, Gongora R, Vasquez JJ, Drummelsmith J, Burchmore R, Roy G, Ouellette M, Gomez MA, Saravia NG.

Mol Biochem Parasitol. 2012 Jun;183(2):166-76. doi: 10.1016/j.molbiopara.2012.03.002. Epub 2012 Mar 17.

PMID:
22449941
27.

Leishmania (Viannia) infection in the domestic dog in Chaparral, Colombia.

Santaella J, Ocampo CB, Saravia NG, Méndez F, Góngora R, Gomez MA, Munstermann LE, Quinnell RJ.

Am J Trop Med Hyg. 2011 May;84(5):674-80. doi: 10.4269/ajtmh.2011.10-0159.

28.

Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis.

Gallego C, Golenbock D, Gomez MA, Saravia NG.

Infect Immun. 2011 Jul;79(7):2871-9. doi: 10.1128/IAI.01388-10. Epub 2011 Apr 25.

29.

Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease.

Castilho TM, Goldsmith-Pestana K, Lozano C, Valderrama L, Saravia NG, McMahon-Pratt D.

Eur J Immunol. 2010 Oct;40(10):2816-29. doi: 10.1002/eji.201040384.

30.

T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species.

Díaz YR, Rojas R, Valderrama L, Saravia NG.

J Infect Dis. 2010 Aug 15;202(3):406-15. doi: 10.1086/653829.

31.

Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species.

Figueroa RA, Lozano LE, Romero IC, Cardona MT, Prager M, Pacheco R, Diaz YR, Tellez JA, Saravia NG.

J Infect Dis. 2009 Aug 15;200(4):638-46. doi: 10.1086/600109.

32.

Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.

Goyeneche-Patino DA, Valderrama L, Walker J, Saravia NG.

Antimicrob Agents Chemother. 2008 Dec;52(12):4503-6. doi: 10.1128/AAC.01075-08. Epub 2008 Sep 29.

33.

Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia.

Rodríguez-Barraquer I, Góngora R, Prager M, Pacheco R, Montero LM, Navas A, Ferro C, Miranda MC, Saravia NG.

Am J Trop Med Hyg. 2008 Feb;78(2):276-82.

PMID:
18256429
34.

Comparative immunohistological analysis of the Montenegro skin test reaction in asymptomatic infection and in acute and chronic cutaneous leishmaniasis.

Guarín N, Palma GI, Pirmez C, Valderrama L, Tovar R, Saravia NG.

Biomedica. 2006 Oct;26 Suppl 1:38-48.

PMID:
17361840
35.

[Leishmaniasis: a public health challenge that demands concerted effort and will (editorial)].

Saravia NG, Nicholls RS.

Biomedica. 2006 Oct;26 Suppl 1:7-9. Spanish. No abstract available.

PMID:
17361835
36.

Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.

Salazar JC, Cruz AR, Pope CD, Valderrama L, Trujillo R, Saravia NG, Radolf JD.

J Infect Dis. 2007 Mar 15;195(6):879-87. Epub 2007 Feb 5.

37.

Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.

Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG.

J Infect Dis. 2007 Feb 15;195(4):602-8. Epub 2007 Jan 11.

PMID:
17230422
38.

Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis.

Acestor N, Masina S, Ives A, Walker J, Saravia NG, Fasel N.

J Infect Dis. 2006 Oct 15;194(8):1160-7. Epub 2006 Sep 8.

PMID:
16991092
39.

Evidence for leishmania (viannia) parasites in the skin and blood of patients before and after treatment.

Vergel C, Palacios R, Cadena H, Posso CJ, Valderrama L, Perez M, Walker J, Travi BL, Saravia NG.

J Infect Dis. 2006 Aug 15;194(4):503-11. Epub 2006 Jul 10.

PMID:
16845635
40.

Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.

Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG.

J Infect Dis. 2006 May 15;193(10):1375-83. Epub 2006 Apr 7.

PMID:
16619185
41.
42.

Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis.

Walker J, Acestor N, Gongora R, Quadroni M, Segura I, Fasel N, Saravia NG.

Mol Biochem Parasitol. 2006 Feb;145(2):254-64. Epub 2005 Oct 28.

PMID:
16325936
43.

Advances in leishmaniasis.

Murray HW, Berman JD, Davies CR, Saravia NG.

Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77. Review.

PMID:
16257344
44.

Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models.

Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, Arteaga L, Coombs G, Mottram J, Travi BL.

Vaccine. 2006 May 8;24(19):4247-59. Epub 2005 Oct 10.

PMID:
16216395
45.

Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes.

El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Papadopoulou B, Légaré D, Ouellette M.

Antimicrob Agents Chemother. 2005 May;49(5):1988-93.

47.
48.

Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana.

Saravia NG, Hazbón MH, Osorio Y, Valderrama L, Walker J, Santrich C, Cortázar T, Lebowitz JH, Travi BL.

Vaccine. 2005 Jan 11;23(8):984-95.

PMID:
15620471
50.

Plumbing the brain drain.

Saravia NG, Miranda JF.

Bull World Health Organ. 2004 Aug;82(8):608-15. Epub 2004 Sep 13. Review.

Supplemental Content

Loading ...
Support Center